Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics, Inc. (GRTX)
:GRTX
GRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.09
Previous CloseN/A
Volume48.38K
Average Volume (3M)64.87K
Market Cap
$1.74M
Enterprise Value$147.32M
Total Cash (Recent Filing)$6.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding75,462,390
10 Day Avg. Volume72,284
30 Day Avg. Volume64,873
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap84.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-38.43
Enterprise Value/Ebitda-8.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics, Inc.’s price range in the past 12 months?
Galera Therapeutics, Inc. lowest stock price was $0.02 and its highest was $0.09 in the past 12 months.
What is Galera Therapeutics, Inc.’s market cap?
Galera Therapeutics, Inc.’s market cap is $1.74M.
When is Galera Therapeutics, Inc.’s upcoming earnings report date?
Galera Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2025 which is in 10 days.
How were Galera Therapeutics, Inc.’s earnings last quarter?
Galera Therapeutics, Inc. released its earnings results on May 19, 2025. The company reported -$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.016.
Is Galera Therapeutics, Inc. overvalued?
According to Wall Street analysts Galera Therapeutics, Inc.’s price is currently Overvalued.
Does Galera Therapeutics, Inc. pay dividends?
Galera Therapeutics, Inc. does not currently pay dividends.
What is Galera Therapeutics, Inc.’s EPS estimate?
Galera Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics, Inc. have?
Galera Therapeutics, Inc. has 75,462,390 shares outstanding.
What happened to Galera Therapeutics, Inc.’s price movement after its last earnings report?
Galera Therapeutics, Inc. reported an EPS of -$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Galera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GRTX
Company Description
Galera Therapeutics, Inc.
Galera Therapeutics, Inc. (GRTX) is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel therapeutics targeting oxygen metabolic pathways. The company is primarily engaged in the development of small molecule therapies that have the potential to transform radiotherapy and chemotherapy by reducing their toxicities, thereby enhancing patient outcomes. Its lead product candidate, avasopasem manganese, is aimed at treating severe oral mucositis (SOM) in patients undergoing radiotherapy for head and neck cancer.
Technical Analysis
Scinai Immunotherapeutics
―
InMed Pharmaceuticals
―
Hyperion DeFi
―
Revelation Biosciences
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
30.40% Insiders
<0.01% Mutual Funds
3.90% Other Institutional Investors
65.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---